BMC Pulmonary Medicine最新文献

{"title":"Age-differentiated comparison of health-related quality of life and impacting factors in patients with COPD receiving long-term home non-invasive ventilation.","authors":"Maximilian Zimmermann, Franziska Vocht, Doreen Kroppen, Daniel S Majorski, Melanie P Berger, Sarah B Stanzel, Johannes F Holle, Falk Schumacher, Tim Matthes, Wolfram Windisch, Maximilian Wollsching-Strobel","doi":"10.1186/s12890-025-03737-3","DOIUrl":"10.1186/s12890-025-03737-3","url":null,"abstract":"<p><strong>Background: </strong>Non-invasive ventilation (NIV) is a well-established treatment for chronic hypercapnic respiratory failure (CHRF). While studies have demonstrated benefits for mortality, hospitalization rates, and health related quality of life (HRQL), evidence is particularly sparse regarding HRQL determinants in the older population.</p><p><strong>Methods: </strong>In a prospective, monocentric observational study, HRQL was assessed using the established Severe Respiratory Insufficiency Questionnaire (SRI). The study was prospectively registered in the German Clinical Trials Register on 17 June 2015 under the registration number DRKS00008759. Patients were categorized into two age-based groups: older patients (≥ 65 years) and younger patients (< 65 years). Multiple linear regression analyses were used to analyze factors on HRQL, including SRI scores, anemia, autonomy impairment, exacerbation history and other factors.</p><p><strong>Results: </strong>237 Patients with COPD with CHRF receiving NIV therapy were included. The mean SRI summary score was 49.9 ± 16.8. with 23.2% (N = 55) suffering from anemia and 36.7% (N = 87) experiencing ≥ 2 exacerbations annually. Autonomy impairment was observed in 49.4% (N = 117) of patients. The updated Charlson Comorbidity Index (uCCI) was 2.2 ± 1.86. No significant differences were found in SRI Summary Scale scores between age groups (p = 0.581), but notable disparities were present in the uCCI (p = 0.014). Multiple regression analysis revealed a negative association of exacerbation history (Young group: -9.2; 95% CI = -14.8/ -3.55 vs. Older group: -6.17; 95% CI = -11.91/ -0.43) and level of autonomy impairment (e.g. Level of Care 2 Young group: -13.91; 95% CI = -21.4/ -6.43 vs. Older group: -14.94; 95% CI = -22.64/ -7.24) on SRI scores with age-related differences. Anemia only had a negative association on the SRI scores in younger patients with COPD (Young group: -7.9; 95% CI = -14.0/ -1.75 vs. Older group: -1.78; 95% CI = -9.21/ 5.65).</p><p><strong>Discussion: </strong>Frequent exacerbations and a higher level of autonomy impairment had a negative association on HRQL across all ages. However only higher levels of impairment (≥ 2) have a detrimental impact on older patients. Anemia was a negative HRQL factor in younger patients, where it was more prevalent. Overall, HRQL was found to be comparably favorable in both older and younger patients, despite age-specific differences in influencing factors.</p><p><strong>Registration of the clinical trial: </strong>The study from which the data were analyzed was prospectively registered in the German Clinical Trials Register (DRKS00008759) on June 17, 2015.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"284"},"PeriodicalIF":2.6,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer incidence in both sexes across global areas: data from 1978 to 2017 and predictions up to 2035.","authors":"Dong-Ning Lu, Yan Jiang, Wan-Chen Zhang, Rong-Kang Du, Ao Zeng, Yi-Mu Wu, Xiao Zhou","doi":"10.1186/s12890-025-03748-0","DOIUrl":"10.1186/s12890-025-03748-0","url":null,"abstract":"<p><strong>Background and aim: </strong>Lung cancer (LC) is one of the most prevalent and fatal malignancies worldwide. With the progress of society, the pathogenic factors, medical diagnosis, and environmental health policies of lung cancer have all changed. Therefore, predicting the incidence trend of LC is of significance for people to understand the future burden of LC.In this study, we aimed to analyze temporal trends in LC incidence across 45 areas from 1978 to 2017, investigate regional and demographic patterns of LC incidence, and predict trends from 2018 to 2035.</p><p><strong>Methods: </strong>Data on annual LC cases and population statistics, stratified by age and sex, were collected from 111 cancer registries in 45 areas across five continents using the Cancer Incidence in Five Continents Plus database. From 1978 to 2017, age-standardized rates (ASRs) per 100,000 individuals were calculated for both sexes and different age groups. A Bayesian age-period-conhort (BAPC) model was applied to forecast ASRs until 2035.</p><p><strong>Results: </strong>From 1978 to 2017, LC ASRs decreased in most areas for men (32/45 areas) but increased for women (37/45 areas), and mainly due to the rising incidence rate among elderly women (> 60 years old). Among men, the country with the largest increase was Cyprus (+ 71.95%), and the largest decrease was Costa Rica (-64%). Among women, France saw the greatest increase (+ 515.15%) while Kuwait had the least (-72.85%). In addition, the LC ASR in high-income areas is higher than that in middle - and low-income areas. However, projections from 2018 to 2035 suggested that only 8 of 45 areas will witness increasing LC ASRs for men, whereas 18 areas will experience ASR increases for women.</p><p><strong>Conclusion: </strong>Overall, global LC incidence is gradually declining. However, considerable disparities exist across areas, sexes, and developmental stages. Therefore, understanding area-specific trends, customizing control measures to local contexts, and conducting screening and early interventions in high-incidence areas and populations are central to overcoming these differences.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"281"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal association between plasma proteins and lung adenocarcinoma: a two-sample mendelian randomization study.","authors":"Weiyuan Zhang, Nan Chen, Changxi Li, Xitian Su, Zhuo Fu, Youshuang Zhong, Huojin Deng","doi":"10.1186/s12890-025-03751-5","DOIUrl":"10.1186/s12890-025-03751-5","url":null,"abstract":"<p><strong>Background: </strong>This study utilized Mendelian randomization (MR) to investigate the causal relationship between circulating plasma proteins and lung adenocarcinoma.</p><p><strong>Methods: </strong>We obtained 734 circulating plasma protein data from genome-wide association studies (GWAS) as exposure factors and extracted single nucleotide polymorphisms (SNPs) as instrumental variables. And we obtained lung adenocarcinoma data (including 11,245 cases and 54,619 controls) from the IEU Open GWAS database as the outcome factor. The main analytical methods used are inverse-variance weighted (IVW) or Wald ratio to assess the causal relationship between circulating plasma protein levels and lung adenocarcinoma. Sensitivity analysis (leave one out method, heterogeneity and pleiotropy tests), external validation analysis, and meta-analysis after MR were used to evaluate the reliability of MR results. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the final screened plasma proteins.</p><p><strong>Results: </strong>Through the preliminary and external validation stages, ICAM5 (OR = 0.92, 95%CI: 0.89-0.95, P = 2.31 × 10^-6), PCYOX1 (OR = 0.89, 95%CI: 0.85-0.93, P = 5.31 × 10^-8), and TYMP (OR = 0.76, 95%CI: 0.66-0.87, P = 5.79 × 10^-5) are negatively correlated with lung adenocarcinoma. Sensitivity analyses, external validation, and post-MR meta-analysis indicated that the MR results were robust. GO and KEGG pathway enrichment analyses demonstrated that these plasma proteins were primarily enriched in pathways such as \"pyrimidine deoxyribonucleoside monophosphate metabolic process\", \"deoxyribonucleoside monophosphate catabolic process\", \"mitochondrial genome maintenance\", and \"Pyrimidine metabolism\".</p><p><strong>Conclusions: </strong>ICAM5, PCYOX1 and TYMP are associated with a decreased risk of lung adenocarcinoma. Plasma proteins may become new biological markers for lung adenocarcinoma, providing new insights into the prevention and treatment of this disease.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"280"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triple overlap of COPD, severe obesity, and high risk of OSA: insights from an NHANES analysis.","authors":"Staci L Orbell, Jonna L Morris, Paul W Scott, Lynn M Baniak, Christopher C Imes, Bomin Jeon, Weiwen Wang, Yue Dong, Patrick J Strollo, Faith S Luyster","doi":"10.1186/s12890-025-03752-4","DOIUrl":"10.1186/s12890-025-03752-4","url":null,"abstract":"<p><strong>Purpose: </strong>With the rising prevalence of severe obesity, the coexistence of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) often progresses to triple overlap syndrome, a condition with significant health implications. However, its prevalence remains poorly understood. Using population-based data from the National Health and Nutrition Examination Survey (NHANES), we examined the prevalence of triple overlap of COPD, severe obesity, and high risk for OSA (HR-OSA) and associated sociodemographic factors among US adults.</p><p><strong>Methods: </strong>A cross-sectional analysis was performed using NHANES data between 2005 and 2008 and 2015-March 2020. COPD diagnosis was collected via self-report questionnaire. HR-OSA was determined by an adapted Multivariable Apnea Prediction index. Severe obesity was defined as a body mass index of ≥ 40.0 kg/m².</p><p><strong>Results: </strong>From 2005 to 2008 to 2015-March 2020, the proportion of participants with triple overlap of COPD, severe obesity, and HR-OSA increased from 0.653% (95% CI, 0.651-0.655%) to 1.560% (95% CI, 1.557-1.563%). During the same period, the increase in the age-standardized prevalence of severe obesity (from 6.298% [95% CI, 6.291-6.305%] to 8.943% [95% CI, 8.936-8.950%]) and HR-OSA (from 58.667% [95% CI, 58.646-58.688%] to 58.776% [95% CI, 58.758-58.794%]; ) exceeded the increase for COPD (from 9.223% [95% CI, 9.215-9.231%] to 10.213% [95% CI, 10.206-10.220%]). Women and those with low family income were more likely to have triple overlap of COPD, severe obesity, and HR- OSA.</p><p><strong>Conclusion: </strong>The triple overlap of COPD, severe obesity, and HR-OSA significantly increased among US adults over the past 15 years, with disparities across different sociodemographic groups.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"282"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exploratory study on the application of nanopore sequencing for detecting Mycobacterium tuberculosis drug resistance in respiratory specimens.","authors":"Niansa Wei, Feiyi Du, Wenjuan Nie, Yingxing Nong, Yanrong Lin, Aichun Huang, Shaoyong Xi, Yiyi Lan, Xiaoyang Luo, Shixiong Yang, Qingdong Zhu","doi":"10.1186/s12890-025-03747-1","DOIUrl":"10.1186/s12890-025-03747-1","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the diagnostic efficacy of nanopore sequencing for Mycobacterium tuberculosis (MTB) drug resistance in respiratory specimens from pulmonary tuberculosis (PTB) patients. It compared it to the Xpert MTB/RIF and fluorescent polymerase chain reaction (PCR) melting curve to explore the validity and feasibility of detecting MTB drug resistance in respiratory specimens.</p><p><strong>Methods: </strong>This study retrospectively analyzed 52 respiratory specimens. The proportional method applied the phenotypic drug susceptibility test (pDST) to respiratory specimens. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), consistency statistic (kappa) with phenotypic drug susceptibility testing (pDST), and the area under the curve (AUC) from the receiver operating characteristic (ROC) curve were calculated for nanopore sequencing, Xpert MTB/RIF, and fluorescent PCR melting curve. These calculations used the pDST results as the reference standard.</p><p><strong>Results: </strong>Among the resistance mutation genes detected by nanopore sequencing, rpoB, and katG were the most frequent, followed by embB, rpsL, gyrA, inhA, ahpC, gyrB, gid, and rrs. In bronchoalveolar lavage fluid (BALF) specimens, nanopore sequencing showed high sensitivity (100.00%,90.32%,82.35%,82.35%,100.00%,76.92%), specificity (70.00%,81.82%,88.00%,96.00%93.75%,93.10%0.100.00%), and AUC values (0.85,0.86,0.85, 0.89,0.97,0.85) for rifampicin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (SM), levofloxacin (LFX), moxifloxacin (MFX). Nanopore sequencing exhibited good detection efficacy (kappa value ≥ 0.70) and perfect diagnostic resistance value (AUC value ≥ 0.85). For RIF, nanopore sequencing showed Kappa values of 0.01 and 0.38 and AUC values of 0.02 and 0.18 higher than the Xpert MTB/RIF and fluorescent PCR melting curve, respectively; for INH, nanopore sequencing had a higher Kappa value of 0.65 and a higher AUC value of 0.32 than the fluorescent PCR melting curve. Nanopore sequencing provided superior overall performance.</p><p><strong>Conclusion: </strong>Nanopore sequencing has significant technical advantages and clinical application potential in detecting MTB drug resistance. Its rapid and highly accurate detection capabilities support early diagnosis and personalized treatment of drug-resistant MTB. As the technology continues to mature and the cost is further reduced, it is expected that nanopore sequencing technology will play a more important role in MTB resistance detection.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"279"},"PeriodicalIF":2.6,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Host and environmental determinants of in-hospital mortality in community-acquired pneumonia: evidence of seasonality, socioeconomic factors, and hospital differentiation in Portugal.","authors":"Ezequiel Pessoa, Cristina Bárbara, Andreia Costa, Paulo Nogueira","doi":"10.1186/s12890-025-03716-8","DOIUrl":"10.1186/s12890-025-03716-8","url":null,"abstract":"<p><strong>Background: </strong>Community-Acquired Pneumonia (CAP) is regarded as a substantial part of the global burden of disease and a public health priority. In addition to host factors, such as demographic characteristics, comorbidities, CAP clinical severity, and in-hospital mortality may also be influenced by factors such as socioeconomic status, seasonal variations, and hospital differentiation. This study aims to analyse trends in hospital mortality among patients hospitalized with CAP in National Health Service (NHS) hospitals in mainland Portugal and the impact of various host and environmental factors on in-hospital mortality.  METHODS: This retrospective cross-sectional study analyzed 378,449 hospitalization episodes with CAP as the primary diagnosis (ICD-9-CM and ICD-10-CM/PCS) in mainland Portugal from 2010 to 2018. Data were sourced from the National Hospital Discharge Database and population census records. Variables included host factors (demographic characteristics, secondary diagnoses, CAP clinical severity indicators, Charlson score) as well as environmental factors, such as seasonality, socioeconomic factors and hospital differentiation. Trend analysis of hospitalization episodes and in-hospital mortality due to CAP was performed. Multivariable logistic regression was used to examine associations with in-hospital mortality, with statistical significance set at p < 0.05.</p><p><strong>Results: </strong>A decrease in the number of hospitalization episodes and in-hospital mortality rate over time was observed. The regression model identified advanced age, male gender, secondary diagnoses, CAP clinical severity, high Charlson score, the summer season, early school leaving rate, higher unemployment rate, and lower hospital differentiation as factors associated with an increased probability of death (p < 0.001).  CONCLUSIONS: Throughout the nine-year period, a steady decline in in-hospital mortality rates was observed. In-hospital mortality exhibited a dual influence, shaped by host factors (such as age, gender, secondary diagnoses, CAP clinical severity, Charlson score) and environmental factors, including the summer season, socioeconomic vulnerability and hospital capabilities. Therefore, effectively reducing CAP in-hospital mortality requires comprehensive policies that focus on at-risk groups and address a broad range of both host and environmental risk factors. These policies should aim to improve healthcare access, increase vaccination coverage, and enhance thermal housing conditions, with particular attention to socially vulnerable individuals.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"278"},"PeriodicalIF":2.6,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"(Pre-) atherosclerotic vessel changes in patients with chronic obstructive pulmonary disease and eosinophilia.","authors":"Leonie Biener, Janne Carolin Drews, Carmen Pizarro, Max Jonathan Stumpf, Nadjib Schahab, Christian Schaefer, Dirk Skowasch","doi":"10.1186/s12890-025-03720-y","DOIUrl":"10.1186/s12890-025-03720-y","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is accompanied by systemic inflammation and an increased risk of cardiovascular diseases, including atherosclerosis and abdominal aortic aneurysms. Eosinophilic inflammation is common in COPD, but little is known about the role of eosinophilia in atherogenesis.</p><p><strong>Objective: </strong>The study aims to investigate a possible link between the blood eosinophil count (BEC) in stable COPD patients and arterial vessel changes of the infrarenal abdominal aorta (AA) and common carotid arteries (CCAs).</p><p><strong>Methods: </strong>One hundred seven patients were acquired. Ultrasonography imaging was employed to assess atherosclerotic plaques and AA diameter, vascular speckle tracking was used to evaluate vessel movement by vascular strains of the AA and CCAs. Patients were divided into two groups, comparing a low (< 300/µl) and high (≥ 300/µl) BEC. The circumferential (rad.) strains and aortic diameter were defined as primary outcome measures.</p><p><strong>Results: </strong>The strains values of the left and right CCA did not differ between the groups (left CCA: 3.0 ± 1.6% vs. 3.6 ± 1.5%, p = .053, right CCA: 3.5 ± 1.8% vs. 4.1 ± 1.8%, p = .127), neither did the aortic diameter (1.88 ± 0.8 vs. 1.79 ± 0.8 cm, p = .674) or atherosclerotic plaque burden. There were lower strain values of the abdominal aorta (3.6 ± 1.5 vs. 2.8 ± 1.4, p = .014), reduced radial displacement (0.16 ± 0.1 vs. 0.11 ± 0.1 mm, p = .011) and an association of BEC and strain values in linear regression analysis (b = -0.001 [95% CI: -0.003-0.001], p = .044), indicating an impaired vascular movement. However, it could not detect an association between BEC and strains of the CCAs (p = .664 resp. .576) or the aortic diameter (p = .672).</p><p><strong>Conclusion: </strong>The study shows no persuasive association between BEC in COPD and vascular strain values or aortic diameter. However, BEC was associated with reduced movement of the AA.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"277"},"PeriodicalIF":2.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective cohort study of adult patients with cystic fibrosis supported with venovenous extracorporeal membrane oxygenation (VV ECMO) at a large German cystic fibrosis center.","authors":"Achim Grünewaldt, Gernot Rohde","doi":"10.1186/s12890-025-03745-3","DOIUrl":"10.1186/s12890-025-03745-3","url":null,"abstract":"<p><strong>Background: </strong>Severe respiratory failure in patients with cystic fibrosis (CF) requiring invasive mechanical ventilation is associated with poor clinical outcomes. The purpose of this study was to evaluate the role of extracorporeal membrane oxygenation (ECMO) in this clinical setting.</p><p><strong>Methods: </strong>In this descriptive retrospective monocentric cohort study, we collected data by using electronic medical records from all patients with CF who received ECMO therapy during the period 2012-2021.</p><p><strong>Setting: </strong>A monocentric setting at the non-surgical intensive care unit of the University Hospital of Frankfurt, Germany (tertiary care level center and nationally certified CF center).</p><p><strong>Results: </strong>During the study period 72 cases of CF patients with intensive care treatment were detected. Of these, 46 cases required mechanical ventilation. Nine patients received ECMO therapy for severe respiratory failure due to pulmonary exacerbation. Eight of the nine patients died in the hospital. This corresponds to an in-hospital mortality rate of 88.9%. None of the patients underwent lung transplantation. The most common CF mutation was the p.Phe508del homo- or heterozygous genotype. Pseudomonas aeruginosa colonization was significantly associated with the in-hospital mortality.</p><p><strong>Conclusions: </strong>ECMO support in CF patients and severe hypoxemic failure is associated with high mortality and its use must take into account the increased risk and poor patient outcome in this clinical setting.</p><p><strong>Clinical trial number: </strong>This was a retrospective, unregistered analysis. A clinical trial number is not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"276"},"PeriodicalIF":2.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung recruitment maneuver improves right and left ventricular function in patients with acute respiratory distress syndrome.","authors":"Alexis Lambour, Yoann Zerbib, Pablo Mercado, Loay Kontar, Bertrand De Cagny, Julien Maizel, Michel Slama, Clément Brault","doi":"10.1186/s12890-025-03735-5","DOIUrl":"10.1186/s12890-025-03735-5","url":null,"abstract":"","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"274"},"PeriodicalIF":2.6,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive impact of chronic obstructive pulmonary disease (COPD) and cardiovascular disease(CVD) on all-cause and disease-Specific mortality: a longitudinal nationwide population-based study.","authors":"Yanling Li, Fuliang Li, Gang Wang, Qingyue Zeng, Ping Xie","doi":"10.1186/s12890-025-03688-9","DOIUrl":"10.1186/s12890-025-03688-9","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are two age-related diseases commonly found in the elderly population, and they are associated with severe health consequences. However, it is currently unclear how patients with either one of these diseases or both diseases simultaneously compare to patients without COPD and CVD in terms of the additive impact on overall mortality, CVD-related mortality, and respiratory system disease-related mortality.</p><p><strong>Method: </strong>The study included 42,317 participants from the National Health and Nutrition Examination Survey (NHANES) spanning from 1999 to 2018. The main objective of the study was to assess the outcomes of all-cause mortality, CVD mortality, and respiratory system disease mortality. We utilized the National Death Index(NDI) Public Access File, up until December 31, 2019, to determine the participants' mortality status and causes of death, with a mean follow-up period of 9.25 years. To ensure the reliability of the results, we employed Cox proportional hazards models to calculate the hazard ratios (HR) and 95% confidence intervals (CI) for mortality rates, along with conducting sensitivity analyses.</p><p><strong>Results: </strong>Among the 42,317 participants, 36,251 individuals (85.7%) had neither COPD nor CVD (COPD-/CVD-). Additionally, 4,252 people (10.0%) had only CVD (COPD-/CVD+), 1,237 people (2.9%) had only COPD (COPD+/CVD-), and 577 people (1.4%) had both COPD and CVD (COPD+/CVD+). Compared to the COPD-/CVD- group, the all-cause mortality rates increased by 1.58-fold (95% CI: 1.46, 1.70), 1.56-fold (95% CI: 1.38, 1.76), and 2.02-fold (95% CI: 1.72, 2.37) in the COPD-/CVD + group, COPD+/CVD- group, and COPD+/CVD + group, respectively, with the COPD+/CVD + group having the highest all-cause mortality risk. Compared to the COPD-/CVD- group, the other three groups showed increased CVD mortality rates, with a HR of 2.35 for the COPD-/CVD + group and COPD+/CVD + group, respectively. Compared to the COPD-/CVD- group, the other three groups had increased respiratory system disease mortality rates, with a HR of 5.00 (95% CI: 3.70, 6.75) for the COPD+/CVD- group and 6.62 (95% CI: 4.56, 9.61) for the COPD+/CVD + group (All trend p-values < 0.0001).</p><p><strong>Conclusion: </strong>Patients with COPD or CVD, or those who have both conditions, are at an increased risk of all-cause mortality, CVD-related mortality, and respiratory system disease-related mortality. Individuals with either of these diseases require more stringent management to prevent the progression of the other disease and reduce mortality rates.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"275"},"PeriodicalIF":2.6,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}